louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT03326570: Effectiveness of Bronchoscopic Interventions for Malignant Airway Obstruction
Official title: Comparative Effectiveness of Bronchoscopic Interventions for Malignant Airway Obstruction
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Lung Cancer
Keywords: Lung cancer
Data collection post bronchoscopy
Lead sponsor: M.D. Anderson Cancer Center
Sponsor class: OTHER
First posted: 2017-10-31
Enrollment: 110
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Participants scheduled for standard of care bronchoscopy at UT MD Anderson Cancer Center in Houston, Texas.

Brief summary: The goal of this clinical research study is learn about side effects and the success of bronchoscopies when performed in cancer patients with and without symptoms.

This is an investigational study.

Up to 110 patients will take part in this study. All will be enrolled at MD Anderson.

Detailed description: If participant agrees to take part in this study, researchers will collect information from participant's medical records.

Length of Study:

Researchers will continue to collect participant's medical information for up to 2 years.

Additional Information:

Participant's data will be kept in a database on a password-protected computer in a secure office. This information will only be available to the study doctors and staff.

Eligibility criteria: Inclusion Criteria:

° All patients undergoing interventional bronchoscopy during the first 12 months will be enrolled, with follow-up occurring out to 2 years from the study startup (the duration of the grant).

Exclusion Criteria:

* Age less than 18 years,
* Inability to participate in telephone follow-up

Primary outcomes:
measure: Time to Any Complication Requiring Treatment
timeFrame: 2 years
Secondary outcomes:
measure: Quality-Adjusted Survival
timeFrame: 2 years
Other outcomes:
measure: Early Intervention
timeFrame: 2 years
measure: Late Intervention
timeFrame: 2 years
Locations:
city: Houston
country: United States
facility: University of Texas MD Anderson Cancer Center
state: Texas
Study officials:
affiliation: M.D. Anderson Cancer Center
name: David Ost, MD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Ong P, Grosu HB, Debiane L, Casal RF, Eapen GA, Jimenez CA, Noor L, Ost DE. Long-term quality-adjusted survival following therapeutic bronchoscopy for malignant central airway obstruction. Thorax. 2019 Feb;74(2):141-156. doi: 10.1136/thoraxjnl-2018-211521. Epub 2018 Sep 25.
Clinical trial NCT02846870: Visually Enhanced Education About Prostate Cancer
Official title: Visually Enhanced Education About Prostate Cancer (VEEP-C): A Randomized Controlled Trial
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Stage I Prostate Cancer
Stage II Prostate Cancer
Stage III Prostate Cancer
Lead sponsor: Vanderbilt-Ingram Cancer Center
Sponsor class: OTHER
Collaborators: name: National Cancer Institute (NCI)
First posted: 2016-07-27
Enrollment: 30
Sex: MALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: SUPPORTIVE_CARE

Brief summary: This randomized clinical trial studies how well visually enhanced education works in improving prostate cancer and treatment knowledge in patients with prostate cancer that has not spread to other places in the body. Visually enhanced education includes pictures, drawings, and photos, may help doctors better convey information about radiation and prostate cancer to patients.

Detailed description: PRIMARY OBJECTIVES:

I. Our goal is to conduct a randomized controlled trial to determine the impact of a visual presentation in the context of a radiation oncologist's discussion with patient during consultation on patient satisfaction at end of consultation visit and at end of treatment, on anxiety at start of treatment, on decision regret following treatment, and on perception of side effects following treatment. Of note, the attending radiation oncologist will be responsible for reviewing the Powerpoint presentation with the patient, taking time to answer any questions that the patient has

OUTLINE: Patients are randomized into 1 of 2 arms.

ARM A (STANDARD EDUCATION): Patients receive a standard prostate cancer radiation oncology consultation.

ARM B (VISUAL ENHANCED EDUCATION): Patients receive a visually enhanced prostate cancer educational Powerpoint presentation including prostate anatomy, pathologic results, surgical options, radiation therapy, and prognosis with pictographs during radiation oncology consultation.

Eligibility criteria: Inclusion Criteria:

* Patient must have non-metastatic, biopsy proven prostate cancer
* Must be referred to radiation oncology clinic

Exclusion Criteria:

* Prior surgery or radiation therapy for prostate cancer
* Patients who are blind are excluded

Primary outcomes:
measure: Decision-Regret - based on Ottawa scale
timeFrame: Up to 12 weeks
Secondary outcomes:
measure: Satisfaction - SCA
timeFrame: baseline, end of treatment, and long-term follow-up
measure: Symptoms based on EPIC-26 short form
timeFrame: baseline, end of treatment, and long-term follow-up
measure: Anxiety - Memorial MAX-PC scale
timeFrame: 1 week
Other outcomes:
Locations:
city: Nashville
country: United States
facility: Vanderbilt University Medical Center
state: Tennessee
Study officials:
affiliation: Vanderbilt University
name: Austin Kirschner, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02320370: Transcranial Electrical Stimulation in the Treatment of Acute Anxiety Induced by Stressful Life Events: A Pilot Study
Official title: Optimizing Electrical Stimulation for Clinical Applications (the OptES Study): Severe Psychological Stress - a Pilot Study (OptES-Stress-pilot)
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Anxiety
Lead sponsor: University of Eastern Finland
Sponsor class: OTHER
First posted: 2014-12-19
Enrollment: 14
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The investigators examine the efficacy of two different transcranial direct current stimulation (tDCS) stimulation protocols in the treatment of acute anxiety in an open-label pilot study in patients who have faced severely stressful life events.

Detailed description: Transcranial direct current stimulation (tDCS) is a novel neuromodulation method that has been observed to be promising in treatment of psychiatric disorders such as depression. Nevertheless, knowledge related to the treatment of psychological stress and its main symptom, anxiety, is very scarce. The investigators examine the efficacy of two different transcranial direct current stimulation (tDCS) stimulation protocols in the treatment of acute anxiety in an open-label pilot study in patients who have faced severely stressful life events.

Eligibility criteria: Inclusion Criteria:

* Age 18-65 years
* Naïve to tDCS
* Right-handed
* Impact of Event Scale Scores ≥ 30

Exclusion Criteria:

* Metal implants inside skull or eye
* Severe skin lesions at the electrode placement area
* History of epilepsy or previous seizures
* Pregnant or breast-feeding
* Pacemaker
* History of intracerebral bleeding during the past six months
* Major psychiatric conditions according to the Structured Clinical Interview for DSM-IV Disorders, i.e., Lifetime diagnoses of bipolar mood disorder or psychotic disorder
* DSM-IV diagnosis for one or more of the following conditions during the past six months: unipolar mood disorder, anxiety disorders, eating disorders, or substance dependence/abuse.
* Use of psychotropic medication (i.e., antipsychotic and antidepressant medications, mood stabilizers, psychostimulants, hypnotics and tranquilizers) during the past six months

Primary outcomes:
measure: Impact of Event Scale (Change in scores of event-related anxiety)
timeFrame: 12 days
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
affiliation: University of Eastern Finland
name: Soili M Lehto, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00655070: Effect of Timi3 Ultrasound on Myocardial Blow Flow in the Hibernating Myocardium
Official title: Evaluation of the Effect of T3US on Myocardial Blow Flow in the Hibernating
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: EARLY_PHASE1
Conditions: Myocardial Ischemia
Keywords: Hibernating Myocardium
Blood Flow
Ultrasound
PET imaging
Lead sponsor: University of California, San Francisco
Sponsor class: OTHER
First posted: 2008-04-09
Enrollment: 9
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: DIAGNOSTIC

Brief summary: The purpose of this study is to evaluate whether the use application of low frequency ultrasound, administered by the Timi3 ultrasound device, increases myocardial blood flow to the heart, in subjects with reduced myocardial blood flow at rest (hibernating myocardium). The primary endpoint of the trial is to assess the increase in myocardial blood flow from baseline to post Timi3 Ultrasound treatment in a hypoperfused region of myocardium. Positron emission tomography (PET) imaging will be used to noninvasively evaluate cardiac blood flow. The hypothesis is that ultrasound increases blood flow in hibernating myocardium.


Eligibility criteria: Inclusion Criteria:

* \>/= 18 years
* Must have reversible resting ischemia, resting non-reversible blood flow defect, or stress-induced ischemia.
* Females with childbearing potential must not be pregnant at the time of the study
* Must provide written informed consent

Exclusion Criteria:

* Unable or unwilling to cooperate with study procedures
* Currently enrolled in another clinical study for which the follow-up period is not complete

Primary outcomes:
measure: Change in myocardial blood flow from baseline to post ultrasound treatment
timeFrame: immediate post treatment
Secondary outcomes:
Other outcomes:
Locations:
city: San Francisco
country: United States
facility: UC San Francisco
state: California
Study officials:
affiliation: University of California at San Francisco
name: Michael W Dae, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03639870: Investigation of the Glaukos® Trabecular Micro-Bypass System, Model iS3, in Subjects With Refractory Glaucoma
Official title: A Prospective, Multicenter Clinical Investigation of the Glaukos® Trabecular Micro-Bypass System, Model iS3, in Subjects With Refractory Glaucoma
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Glaucoma
Keywords: refractory
Lead sponsor: Glaukos Corporation
Sponsor class: INDUSTRY
First posted: 2018-08-21
Enrollment: 65
Sex: ALL
Minimum age (years): 45
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Intervention model description: The iStent infinite Trabecular Micro-Bypass System Model iS3 is a sterile, single-use injector system that is pre-loaded with three G2-W stents, and is designed to deliver the stents into Schlemm's canal. The three G2-W stents are heparin-coated and manufactured from implant grade titanium.
Primary purpose: TREATMENT

Brief summary: Prospective, multi-center, single-arm clinical trial to evaluate the safety and effectiveness of the Glaukos® Trabecular Micro-Bypass System Model iS3 (three stents per study eye) in subjects with refractory glaucoma.

Detailed description: This is a prospective, multi-center, single arm, open-label clinical trial of the iS3 system. Up to 65 qualified subjects will be implanted with three G2-W stents in one eye and will be followed for 12 months postoperatively.

Eligibility criteria: Inclusion Criteria:

* Diagnosis of refractory open-angle glaucoma (including pigmentary and pseudoexfoliative glaucoma) that is uncontrolled despite medical therapy and/or prior conventional incisional intraocular glaucoma surgeries.
* Phakic or pseudophakic.
* Males or females, 45 years of age or older.

Exclusion Criteria:

* Traumatic, uveitic, neovascular, or angle-closure; or glaucoma associated with vascular disorders.
* Active corneal inflammation or edema.
* Retinal disorders not associated with glaucoma.

Primary outcomes:
measure: Primary effectiveness endpoint
timeFrame: Month 12 postoperative
Secondary outcomes:
Other outcomes:
Locations:
city: Dallas
country: United States
facility: Glaucoma Associates of Tx
state: Texas
Study officials:
affiliation: Glaukos Corporation
name: Kerry Stephens, O.D.
role: STUDY_CHAIR
References:
Clinical trial NCT06891170: B Cell Responses in COVID-19
Official title: B Cell Responses in COVID-19: Generation of SARS-CoV-2 Neutralizing Human Monoclonal Antibodies to Efficiently Contrast Wild-type and Emerging Variants.
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: COVID 19
Lead sponsor: Fondazione IRCCS Policlinico San Matteo di Pavia
Sponsor class: OTHER
First posted: 2025-03-24
Enrollment: 4
Sex: ALL
Minimum age (years): 18
Maximum age (years): 90
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Vaccinated or recovered subjects from COVID-19

Brief summary: In this study, we will develop techniques to optimize the in vitro production of human monoclonal antibodies.


Eligibility criteria: Inclusion Criteria:

* Age \>18 at time of signing informed consent form
* Signed informed consent form

Exclusion Criteria:

* Ongoing drug abuse
* Active or history of neoplastic malignancy
* Active autoimmune disease ongoing treatment with immunosuppressive therapy
* Ischemic heart disease
* Evidence of positive HIV, HCV, HBV test
* Diabetes
* Failure to sign informed consent form

Primary outcomes:
measure: Optimization of the method to obtain human mAbs neutralizing COVID-19.
timeFrame: From enrollment to 24 weeks
Secondary outcomes:
Other outcomes:
Locations:
city: Pavia
country: Italy
facility: Fondazione IRCCS Policlinico San Matteo di Pavia
Study officials:
References:
Clinical trial NCT04480970: Placement of Nasogastric Tubes for Gastric Decompression in Patients With Bronchiolitis
Official title: Placement of Nasogastric Tubes for Gastric Decompression in Patients With Bronchiolitis
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Bronchiolitis
Lead sponsor: Arkansas Children's Hospital Research Institute
Sponsor class: OTHER
First posted: 2020-07-22
Enrollment: 60
Sex: ALL
Minimum age (years): 1
Maximum age (years): 23
Standard ages: CHILD
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: This study aims to evaluate whether placing nasogastric tubes for gastric decompression improves respiratory distress for patients with bronchiolitis who are receiving oxygen via high-flow nasal cannula.

Detailed description: All patients will be consented per IRB procedure. The study will be a prospective study. Study participants will be enrolled after placement on high flow nasal cannula. The respiratory therapist or study staff will use a bronchiolitis scoring tool, the Marlais Risk of Admission Score, to assess the respiratory status of patients after placement on high flow nasal cannula, and prior to placement of NG tube to establish a baseline measurement. This tool includes the following components: respiratory rate, oxygen saturation, heart rate, age, and length of illness. An NG tube will then be placed. Thirty minutes and sixty minutes after placement of the NG tube, the respiratory therapist or study team will again use this scoring tool to assess the respiratory status of the patient. After 60 minutes the study will be concluded. As subject will be requiring oxygen use, admission to an inpatient unit is required. The NG tube will be removed at the discretion of the provider or the admitting physician, who may choose to keep it in at their discretion.

Eligibility criteria: Inclusion Criteria:

* Diagnosis of bronchiolitis by the attending physician
* On high flow nasal cannula (4 liters or greater)
* Ages 0 months to 23 months

Exclusion Criteria:

* Diagnosis of bacterial pneumonia
* History of cranio-facial anomalies
* History of congenital heart disease
* History of G-tube dependence
* History of short gut syndrome
* History of tracheostomy or current tracheostomy

Primary outcomes:
measure: Respiratory status
timeFrame: 60 minutes
Secondary outcomes:
Other outcomes:
Locations:
city: Little Rock
country: United States
facility: Arkansas Children's Hospital
state: Arkansas
Study officials:
affiliation: AR Children's Hospital
name: David Spiro, MD, MPH
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06412770: Effect of Tai Chi on Symptoms in Hemodialysis Patients
Official title: Director, World Health Organization (WHO)
Study type: INTERVENTIONAL
Overall status: NOT_YET_RECRUITING
Phase: NA
Conditions: Dialysis; Complications
Chinese Medicine
Quality of Life
Lead sponsor: Chengdu University of Traditional Chinese Medicine
Sponsor class: OTHER
First posted: 2024-05-14
Enrollment: 80
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: OTHER

Brief summary: The goal of this clinical trial is to learn about the effect of Tai Chi on symptoms in hemodialysis patients.The main question\[s\] it aims to answer are: the effect of Tai Chi on symptoms or the quality of life in hemodialysis patients .Participants will be divided into three groups, one group will be asked to do Tai Chi for 30 minutes three times a week, and the other group will be asked to do Tai Chi imagery for 30 minutes three times a week. The comparison group will be given usual care. Researchers will compare the efficacy of symptoms and quality of life in dialysis patients in each group.


Eligibility criteria: Inclusion Criteria:

* Age≥ 18;
* Dialysis age≥ 3 months;
* Survival≥ 12 months;
* The patient has the ability to move independently, can learn independently, and has no reading and comprehension disabilities;
* Informed consent

Exclusion Criteria:

* Inability to move autonomously;
* Have a mental disorder;
* Other serious complications occur

Primary outcomes:
measure: Evaluation of life quality after treatment
timeFrame: Assessment was performed at 4, 8, and 12 weeks after treatment
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT04749875: Study of Leukocyte Populations in Patients With Chronic Inflammatory
Official title: Study of Leukocyte Populations in Patients With Chronic Inflammatory
Study type: OBSERVATIONAL
Overall status: NOT_YET_RECRUITING
Conditions: Systemic Autoimmune Disease
Chronic Inflammatory Rheumatism
Sjogren's Syndrome
Spondyloarthritis
Rheumatoid Arthritis
Systemic Lupus Erythematosus
Keywords: leukocytes
macrophages
lymphocytes
rare systemic autoimmune diseases
chronic inflammatory rheumatism
Lead sponsor: Assistance Publique - Hôpitaux de Paris
Sponsor class: OTHER
First posted: 2021-02-11
Enrollment: 1500
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Adult patients with chronic inflammatory rheumatism and rare systemic autoimmune diseases

Brief summary: Exploration of pathophysiological mechanisms in chronic inflammatory rheumatism and rare systemic autoimmune diseases with the objective of identifying therapeutic targets.

Detailed description: The primary objective is to characterization of the quantitative and qualitative specificities of the different leukocyte sub-populations in patients with chronic inflammatory rheumatism and rare systemic autoimmune diseases. We will perform an exploratory descriptive study whom primary endpoint will be to assess by FACS the phenotype of the specific leukocyte subsets. In addition, we will characterize the protein and transcriptomic signature associated with the conditions for which we have obtained preliminary data showing their potential involvement in autoimmunity (i.e: IL7 pathway, IFN signature).

Eligibility criteria: Inclusion Criteria:

* Age ≥18 years
* Patient who did not express his opposition
* Patients with chronic inflammatory rheumatism and rare systemic autoimmune diseases (pSS, lupus, scleroderma, myositis, unclassified connectivitis) diagnosed according to the usual criteria.
* Weight\> 35 kg

Exclusion Criteria:

* Corticosteroid treatment\> 10 mg / day
* Pregnant patient
* Patients under legal protection
* Beneficiary of the state medical aid

Primary outcomes:
measure: Characterization of the quantitative and qualitative specificities of the different leukocyte subpopulations in patients with chronic inflammatory rheumatism and rare systemic autoimmune diseases
timeFrame: At the end of the study (5 years)
Secondary outcomes:
measure: Protein study (ELISA on serum) : IL7
timeFrame: At the end of the study (5 years)
measure: Transcriptome study (RNA) : mRNA levels
timeFrame: At the end of the study (5 years)
measure: Genomic study (DNA) : SNPs
timeFrame: At the end of the study (5 years)
Other outcomes:
Locations:
city: Le Kremlin-Bicêtre
country: France
facility: CHU Bicêtre
Study officials:
affiliation: APHP
name: Gaetane Nocturne
role: PRINCIPAL_INVESTIGATOR
References: